Century Therapeutics, Inc. (IPSC) - Q2 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2026. Century Therapeutics, Inc. is an innovative biotechnology company developing allogeneic cell therapies for autoimmune diseases (including Type 1 diabetes) and cancer using induced pluripotent stem cells (iPSCs). The company is classified as a non-accelerated filer, smaller reporting company, and emerging growth company. As of August 3, 2026, there were 181,075,321 shares of common stock outstanding.
Key Financial Metrics
| Metric | Q2 2026 (3 Months) | YTD 2026 (6 Months) | YTD 2025 (6 Months) |
|---|---|---|---|
| Collaboration Revenue | $0 | $0 | $109.2 million |
| Net Loss | $(34.6) million | $(56.2) million | $44.0 million (Income) |
| Operating Expenses | $36.5 million | $60.2 million | $69.7 million |
| Research & Development (R&D) | $19.6 million | $36.7 million | $53.4 million |
| General & Administrative (G&A) | $5.8 million | $12.4 million | $16.2 million |
| Loss on Lease Termination | $11.1 million | $11.1 million | $0 |
| Cash & Cash Equivalents | $49.6 million (as of June 30, 2026) | ||
| Total Investments | $147.5 million (as of June 30, 2026) | ||
| Total Liquidity | $197.2 million (as of June 30, 2026) | ||
| Net Cash Used in Operating Activities | $(45.1) million (YTD 2026) |
Material Changes vs. Prior Period
- Revenue Shift: Collaboration revenue dropped to zero in 2026 following the termination of the Bristol-Myers Squibb (BMS) agreement in March 2025. The prior year period included a one-time recognition of $109.2 million in revenue upon that termination.
- Operating Loss: The company reported a net loss of $56.2 million for the six months ended June 30, 2026, compared to net income of $44.0 million in the same period in 2025. This swing is primarily due to the absence of BMS revenue and a significant non-cash loss on lease termination.
- Expense Reduction: R&D expenses decreased by $16.7 million year-over-year (YTD), driven by a reduction in personnel costs ($8.4 million) and facility costs ($3.8 million) following portfolio prioritization. G&A expenses decreased by $3.8 million YTD.
- Lease Termination Loss: A one-time loss of $11.1 million was recognized in Q2 2026 due to the partial termination of the company's Philadelphia headquarters lease and the disposal of related assets.
- Capital Raise: In January 2026, the company completed a private placement raising approximately $126.4 million in net proceeds, significantly bolstering liquidity compared to the prior year.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management believes current cash, cash equivalents, and investments ($197.2 million) are sufficient to fund operations into the first quarter of 2029. However, the company anticipates needing additional financing in the future for clinical trials and commercialization.
- Product Pipeline:
- CNTY-813 (Lead Program): An iPSC-derived islet replacement therapy for Type 1 Diabetes. The company expects to submit an Investigational New Drug (IND) application in Q4 2026, with initial clinical data anticipated in H2 2027.
- CNTY-308: A CD19-targeted CAR-iT cell therapy for B-cell-mediated diseases. Expected to enter the clinic in 2026 pending regulatory clearance.
- Key Risks:
- Capital Requirements: The company has a history of net losses and will require significant additional capital to advance its pipeline. Failure to raise capital could materially adversely affect operations.
- Development Risks: Preclinical and clinical development involves substantial uncertainty. There is no guarantee that product candidates will receive regulatory approval or achieve commercial success.
- Lease Guaranty: The company executed a guaranty for a replacement tenant in its Philadelphia facility with potential future payments of approximately $14.9 million, though the likelihood of performance is currently considered remote.
Investor Verification Checklist
- Cash Runway: Verify the $197.2 million liquidity position and the specific assumptions used to project sufficiency through Q1 2029.
- Lease Termination Impact: Confirm the details of the $11.1 million loss on lease termination and the remaining obligations under the revised Philadelphia lease and the Watertown, MA lease.
- Private Placement Terms: Review the terms of the January 2026 private placement, specifically the warrant exercise prices ($2.60) and expiration triggers (linked to CNTY-813 Phase 1 data).
- R&D Spend Efficiency: Assess the sustainability of the reduced R&D burn rate ($36.7M YTD vs $53.4M prior year) and whether it aligns with the accelerated timeline for the CNTY-813 IND submission.
- Contingent Liabilities: Monitor the status of the Clade Therapeutics contingent consideration liability, which was derecognized in Q2 2026 due to an expired earn-out period.